Table 3.

Larger studies of bortezomib containing regimens in light chain amyloidosis

Study	Treatment regimen	Study design	N	Patient characteristics	Overall response (%)	Complete response (%)	PFS	OS
Kastritis 2010 [1]	Bortezomib with or without dexamethasone	Retrospective analysis	94	19% untreated, 81% previously treated; 69% refractory	71	25	25.5 months	1-year survival: 76%
Palladini 2014 [2]	BMD MD	Matched case-control study	87 87	Upfront therapy	69 vs. 51	42 vs. 19		Died 39% vs. 55% at median follow-up 26 months
Reece 2011 [3]	Bortezomib1.6 mg/m2 once weekly vs. 1.3 mg/m2 twice weekly	Phase I/II study	70	Relapsed	68.8 vs. 66.7	37.5 vs. 24.2	1-year PFS: 72.2% vs. 74.6%	1-year survival rates: 93.8% vs. 84.0%
Kastritis 2017 [5]	VD vs. VCD	Retrospective comparison	59 42	Upfront therapy	68 vs. 78 (p = 0.26)	27 vs. 21	ND	33 vs. 36 months (p = 0.45)
Palladini 2015 [6]	VCD	Retrospective study	230	Upfront therapy	60	21	Median time to SLT or death: 13 months	OS at 3 years: 55%
Venner 2014 [7]	VCD vs. CTD	Matched comparison	69 vs. 69	Upfront therapy	71.0 vs. 79.7 (p = 0.32).	(40.5) vs. CTD (24.6), p = 0.046	Median PFS: NR vs. 19.2 months (p = 0.028)	1-year OS 96% vs. 92% (p = 0.40)

BMD bortezomib plus melphalan plus dexamethasone, CTD cyclophosphamide, thalidomide, and dexamethasone, MD melphalan plus dexamethasone, ND not done, NR not reached, OS overall survival, PFS progression-free survival, SLT second-line therapy, VCD bortezomib plus cyclophosphamide plus dexamethasone, VD bortezomib plus dexamethasone, VGPR very good partial response